News

Under the deal, OA Centers of America will include Gensco’s patented Transdermal products (SpeedGel Rx and LiDORx) as an option to show improved patient outcomes and economic value

The results showed patients with relapsed/refractory CLL taking venetoclax in combination with rituximab, had an overall response rate (ORR) of 84%. In addition, six patients stopped venetoclax after

Currently, the company is carrying out a multicenter, randomized, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SER-109 in prevention of recurrent CDI. The

InSite is seeking marketing approval of BromSite in the United States. In its confirmatory Phase 3 clinical trials, BromSite achieved statistically significant superiority to vehicle in alleviating ocular

The amendment enhances MPP’s current licence by allowing South African manufacturers to join Indian and Chinese companies in developing generics for low- and middle-income countries. "We welcome the

The Phase 3 clinical trial program, known as COGNITIV SZ, is designed to assess the safety and efficacy of encenicline compared to placebo as a pro-cognitive therapy in

The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being

Under the agreement, Abbott will offer its HIV viral load tests – which monitor the amount of HIV in a person’s blood – at reduced prices to help

The deal, facilitated by J&J Innovation, will see the two firms jointly develop and commercialize RNA-based drug products to treat specified diseases using Arcturus’ UNA Oligomer chemistry and